Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Accomplishments and challenges in stem cell imaging in vivo. [PDF]
, 2019 Stem cell therapies have demonstrated promising preclinical results, but very few applications have reached the clinic owing to safety and efficacy concerns.
Bose, Rajendran JC, Mattrey, Robert F
core
Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs [PDF]
, 2020 Stefania Scala, Roberto Pacelli
openalex +1 more source
Molecular Oncology, EarlyView.Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates
Advanced ScienceChemically modified proteins have diverse applications; however, conventional chemo‐selective methods often yield heterogeneously labeled products. To address this limitation, site‐specific protein labeling holds significant potential, driving extensive ...
Sooin Kim +9 more
doaj +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Medicare Part D: Simplifying the Program and Improving the Value of Information for Beneficiaries [PDF]
, 2008 Examines options for simplifying Medicare's prescription drug benefit, including streamlining benefit procedures and descriptions; further standardizing benefit parameters, especially cost-sharing rules; and modifying rules on plan ...
Jack Hoadley
core
From Off-Label to Repurposed Drug in Non-Oncological Rare Diseases: Definition and State of the Art in Selected EU Countries [PDF]
, 2017 Paola Minghetti +5 more
openalex +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. [PDF]
J Gen Intern Med, 2020 Desai B, Hong K, Powers JH, Doshi P.
europepmc +1 more source